BETA

Beta Drugs Ltd.

NSE: BETA

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

2,315.60+38.4 (+1.69%)

24 Jul, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

67.9 / 100

Value Score

14.3 / 100

Price Momentum Score

89.6 / 100

QVM Score

62.0 / 100

Key Metrics

Market Cap

2337.60

P/E (TTM)

51.28

P/B

9.55

P/S (TTM)

5.70

EV/EBITDA

28.14

CAPE (5Y)

64.83

ROE (TTM)

18.78

ROCE (TTM)

16.08

ROA (TTM)

8.90

Avg 3Y ROE

22.92

Earnings 3Y CAGR

10.38

Sales 3Y CAGR

19.22

Sales 5Y CAGR

27.08

Debt/Equity

0.60

Consensus TP

Strong Buy %

Promoter Holding

59.10

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Beta Drugs Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 89.6 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

89.6 / 100

High ROE

The company reported strong ROE of 18.78% for 12-month ended 30 Jun 2026

What is ROE (FY)?

High operating margin

The company reported strong operating margin of 15.99% for 12-month ended 30 Jun 2026

What is Operating profit margin?

Low Debt to Equity

The company has low Debt to Equity of 0.6 as on 30 Jun 2026

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 10 financial years

What is Dividend streak?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 51.28 indicates that the stock is expensive on a standalone basis and is at a 64.99% premium to industry median P/E

What is P/E Ratio?

Median: 31.08

Value 51.28

-43.163369.02

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of 6.2% for 12-month ended 30 Jun 2026 and the growth was 14.67 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 20.87

Value 6.2

-0.87151.63

Low EPS growth and in line with median growth of industry

The company delivered low EPS growth of -12.09% for 12-month ended 30 Jun 2026 and the growth was 0.0 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Company's earnings are of moderate quality

Earnings quality score of 43.1 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

43.1 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Beta Drugs Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Beta Drugs Ltd. Shareholding Pattern

Quarterly breakdown of Beta Drugs Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	66.08	66.08	66.61	66.68	66.68	66.68	66.68	66.71	66.71	66.71	66.71	66.71	66.73	66.73	66.73	66.73	66.73	66.73	66.73	66.73	66.73	66.73	66.73	64.90	64.63	59.10
Indian Promoter	66.08	66.08	66.61	66.68	66.68	66.68	66.68	66.71	66.71	66.71	66.71	66.71	66.73	66.73	66.73	66.73	66.73	66.73	66.73	66.73	66.73	66.73	66.73	64.90	64.63	59.10
Foreign Promoter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	0.00	0.00	0.00	0.00	0.00	0.27	0.28	0.29	0.29	0.29	0.33	0.29	0.29	0.29	0.32	0.32	0.36	1.00	1.30	1.30	1.05	1.14	1.18	3.02	3.30	7.24
Mutual Funds / UTI	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.27	0.28	0.29	0.29	0.29	0.29	0.29	0.29	0.29	0.32	0.32	0.32	0.90	1.15	1.15	0.90	0.90	0.90	1.14	1.16	1.02
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.00	0.00	0.00	0.00	0.00	0.04	0.10	0.15	0.15	0.15	0.24	0.28	1.88	2.14	6.22
Non-Institution	33.92	33.92	33.39	33.32	33.32	33.06	33.03	33.00	33.00	33.00	32.96	33.00	32.98	32.97	32.95	32.94	32.91	32.27	31.96	31.96	32.21	32.12	32.08	32.08	32.07	33.66
Bodies Corporate	10.75	10.87	8.93	8.73	9.33	9.02	8.60	8.59	8.62	8.67	8.70	8.59	8.55	8.71	8.72	8.72	8.65	8.60	8.53	8.57	8.56	8.65	8.55	8.54	8.54	7.84
Others (incl. Retail) No. of shareholders	23.17 525	23.05 523	24.46 515	24.59 514	23.99 516	24.04 484	24.43 520	24.41 650	24.38 734	24.33 1,264	24.26 1,375	24.41 1,419	24.43 1,399	24.26 1,410	24.23 1,671	24.22 1,872	24.26 2,068	23.67 2,266	23.43 2,507	23.39 2,815	23.65 2,991	23.47 3,072	23.53 3,126	23.54 3,624	23.53 4,659	25.82 7,275

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

Beta Drugs Ltd. is not part of any tracked index.

Prominent Investor Holdings

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Beta Drugs Ltd. shares as reported to NSE and BSE.

Name	Date	Type	Price	Qty.	Value
AIRAVAT CAPITAL TRUST II	13 Nov 2025	buy	₹ 1,686.00	1.56 lac	₹ 26.29 cr
NEERAJ BATRA	13 Nov 2025	sell	₹ 1,686.00	1.85 lac	₹ 31.21 cr

Corporate Actions

History of Beta Drugs Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Bonus1 new shares for 20 existing shares
Ex-date: 26th Mar 2025Announced on: 5th Feb 2025

Company Profile

Overview of Beta Drugs Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Beta Drugs Limited is an India-based oncology medicine manufacturing company. The Company specializes in the intricate field of complex chemical synthesis for anti-cancer bulk drugs and finished dosages. The Company operates through one segment, Pharmaceuticals. Its product category includes cosmece...

Key personnel

Mr. Nipun Arora

Chief Financial Officer

Ms. Rajni Brar

Chief Compliance Officer, Company Secretary

Mr. Rahul BatraD

Chairman of the Board, Managing Director

Mr. Varun BatraD

Joint Managing Director, Whole Time Director

Mr. Ashutosh ShuklaD

Whole Time Director

Mr. Balwant SinghD

Whole Time Director

Mr. Ajay MahipalD

Non-Executive Director

Mrs. Monica JainD

Additional Independent Director

View all

Incorporated on

21 Sep 2005

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

IPO date

12 Oct 2017

Free Float

1,01,36,890

Website

https://betadrugslimited.com

Phone no.

+911795236196

Address

Sco 184, Sector 5, Panchkula, PANCHKULA, 134114, India

Frequently Asked Questions

What is the current share price of Beta Drugs Ltd.?

The current share price of Beta Drugs Ltd. is ₹ 2,315.60 as of 24 Jul 2026.

What is the market capitalisation of Beta Drugs Ltd.?

The market capitalisation of Beta Drugs Ltd. stands at ₹ 2,337.60 Cr.

What is the PE ratio of Beta Drugs Ltd.?

The Price-to-Earnings (PE) ratio of Beta Drugs Ltd. is 51.28 as of the latest trailing twelve months data.

What is the ROE and ROCE of Beta Drugs Ltd.?

Beta Drugs Ltd. has a Return on Equity (ROE) of 18.78% and a Return on Capital Employed (ROCE) of 16.08% as per the latest financial reports.

What is the 52-week high and low of Beta Drugs Ltd.?

The 52-week high of Beta Drugs Ltd. is - and the 52-week low is -.

What is the dividend yield of Beta Drugs Ltd.?

The dividend yield of Beta Drugs Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Beta Drugs Ltd.?

Foreign Institutional Investors (FII) hold 1.02%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 25.82% of Beta Drugs Ltd. shares.

What sector does Beta Drugs Ltd. belong to?

Beta Drugs Ltd. operates in the Healthcare sector.

What is the beta of Beta Drugs Ltd.?

The beta of Beta Drugs Ltd. is 0.89, indicating its price volatility relative to the broader market. Over the past 1 year, Beta Drugs Ltd. has delivered an absolute return of 38.08%.

What is the RSI of Beta Drugs Ltd.?

The 14-day Relative Strength Index (RSI) of Beta Drugs Ltd. is 59.20, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Beta Drugs Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Beta Drugs Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile

Corporate Actions

Holdings and Presence